Bladder sparing: Risk-enabled therapy after initiating neoadjuvant chemo allows active surveillance of some MIBC

Genomic profiling of penile squamous cell carcinoma reveals major biomarkers for efficacy of immunotherapy

Pembrolizumab shows notable antitumour activity for patients with high-risk non–muscle-invasive bladder cancer

Latest in PARP inhibitors and combination therapies for prostate cancer

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC

Plasma miR371 detects MRD and early relapse of germ cell tumours

Comparative cost-effectiveness of alternative imaging and surveillance schedules for testicular seminoma

Adaptive image-guided radiotherapy in muscle-invasive bladder cancer shows low toxicity and good outcomes

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Nivolumab and salvage nivolumab plus ipilimumab for aRCC

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients